SEC Form 4 · accession 0001179110-17-006989
AMAG PHARMACEUTICALS INC. · AMAG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William K Heiden
Officer — President & CEO · Director
Period of report
May 8, 2017
Accepted (ET)
May 10, 2017 · 4:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000792977
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 8, 2017 | F | 19,085 | $18.55 | D | 272,561 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 18,700 restricted stock units ("RSUs") on January 2, 2017, 9,999 RSUs on February 26, 2017, 3,900 RSUs on February 27, 2017, 3,600 RSUs on February 28, 2017 and 11,998 RSUs on March 1, 2017. Due to the black-out policies implemented by AMAG Pharmaceuticals, Inc. (the "Issuer"), the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until May 8, 2017, at which time an aggregate of 19,085 shares were withheld to satisfy the reporting person's applicable tax obligations.